In silico identification of therapeutic compounds against microRNA targets in drug-resistant pancreatic ductal adenocarcinoma.
Pancreatic ductal adenocarcinoma (PDAC) is a major health issue that has been eluding efforts to identify viable therapeutic treatment options. Besides having the lowest survival rate among all types of cancer, almost all conventional methods of treatment are futile against this condition, leaving patients to succumb to this ailment faster than ever. As it is increasingly becoming difficult to come up with new compounds for the treatment of various diseases, alternative solutions are required for tackling these problems. In this study, publically available miRNA and gene expression data were used to identify common elements that were present in gemcitabine-resistant PDAC cell lines. By selecting overexpressed genes involved in pancreatic cancer and cancer pathways in general, potential drug candidates for the treatment of PDAC were identified. In this study, 21 differentially expressed miRNAs were identified from PANC-1 cell line treated with gemcitabine. Pathway analysis revealed that MET and PPARG were overexpressed in cancer-related pathways, including pancreatic cancer, and could be targeted for PDAC treatment. Using CMap, fisetin was identified a likely candidate drug for the treatment of PDAC. Docking studies indicated that fisetin was bound to c-Met and PPARG with an XP G score of -12.819 and -7.021 kcal/mol, respectively. As miRNAs have increasingly been shown to part take in important cancer-related processes and pathways, researching drug development methods based on miRNA targets could be beneficial for pharmaceutical industries. Communicated by Ramaswamy H. Sarma.
['Aier|Imlimaong|I|', 'Semwal|Rahul|R|', 'Sharma|Anju|A|', 'Varadwaj|Pritish Kumar|PK|']
D021441:Carcinoma, Pancreatic Ductal D045744:Cell Line, Tumor D003198:Computer Simulation D015972:Gene Expression Regulation, Neoplastic D006801:Humans D035683:MicroRNAs D010190:Pancreatic Neoplasms D004364:Pharmaceutical Preparations
microRNA pancreatic ductal adenocarcinoma Pancreatic cancer drug repurposing drug resistance